Skip to search boxSkip to navigationSkip to main content

Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease

*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

<p>Sickle cell disease (SCD) is a pathophysiological condition of chronic hemolysis, oxidative stress, and elevated inflammation. The transcription factor Nrf2 is a master regulator of oxidative stress. Here, we report that the FDA-approved oral agent simvastatin, an inhibitor of hydroxymethyl-glutaryl coenzyme A reductase, significantly activates the expression of Nrf2 and antioxidant enzymes. Simvastatin also induces fetal hemoglobin expression in SCD patient primary erythroid progenitors and a transgenic mouse model. Simvastatin alleviates SCD symptoms by decreasing hemoglobin S sickling, oxidative stress, and inflammatory stress in erythroblasts. Particularly, simvastatin increases cellular levels of cystine, the precursor for the biosynthesis of the antioxidant reduced glutathione, and decreases the iron content in SCD mouse spleen and liver tissues. Mechanistic studies suggest that simvastatin suppresses the expression of the critical histone methyltransferase enhancer of zeste homolog 2 to reduce both global and gene-specific histone H3 lysine 27 trimethylation. These chromatin structural changes promote the assembly of transcription complexes to fetal γ-globin and antioxidant gene regulatory regions in an antioxidant response element-dependent manner. In summary, our findings suggest that simvastatin activates fetal hemoglobin and antioxidant protein expression, modulates iron and cystine/reduced glutathione levels to improve the phenotype of SCD, and represents a therapeutic strategy for further development.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Article number

337

Journal (Volume, Issue Number)

Antioxidants (Volume 13, Issue 3)

Publication milestones

  • Published - 03/2024

Publication status

Published - 03/2024

Publication IDs

  • Scopus: 85188663506

Publication metrics

Metrics

Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Mentions
2
Citation count
7
Captures
5

Funding Details

This research was funded by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases R01DK119762 and R01DK139694 (X.Z.), the Augusta University Intramural Pilots Project (IGPP00055) (X.Z. and B.P.), and the National Heart, Lung, and Blood Institute R01HL149365 (B.P.).
FundersFunding numbers
NIH
-
NIDDK
R01DK119762, R01DK139694
Augusta University
IGPP00055
NHLBI
R01HL149365